The July 2026 edition registered 725 clinical trials, of which 61 were multi-site studies. This signals continued appetite for research that spans more than a single location. Within that activity, 43 studies were India-only and 18 were global, reflecting the domestic research momentum that has become a recurring theme in these reports.
On the therapeutic front, oncology led the way, followed by Metabolic & Endocrinology, CNS/Neurology, Cardiology, and Gastroenterology. It’s a spread that mirrors India’s shifting disease burden and the widening set of priorities that sponsors are bringing to the country. Global Pharma and Indian Pharma remained the leading sponsor groups, underscoring that India continues to attract both multinational programs and homegrown research investment.
The Geography Keeps Shifting
Tier 2 cities hosted 343 sites, outpacing Tier 1 cities at 268 while continuing a pattern that has held month after month.
This isn’t a one-off. It points to a sustained shift toward broader geographic participation in multi-site clinical research: trials reaching beyond the traditional metros, into cities that bring new investigators, new sites, and access to patient populations that were historically underrepresented. For sponsors and CROs planning site strategy, it’s a shift worth designing around rather than reacting to.
Looking Beyond the Numbers
Taken together, the July data reinforces a trend IndiaTrialPulse has surfaced consistently: clinical research in India is becoming more distributed, more diverse, and more accessible.
The continued rise of Tier 2 cities, paired with strong domestic activity and an expanding set of therapeutic priorities, describes an ecosystem that is steadily building the foundation for the next generation of clinical trials. The infrastructure, the investigator base, and the sponsor confidence are all trending in the same direction.
From data to intelligence
At StriderDCT, we believe the future of clinical research lies not only in generating data, but in transforming it into intelligence teams can act on. IndiaTrialPulse is one expression of that belief. It is a monthly read on the ecosystem that helps decision-makers see the shape of what’s coming, not just what’s already happened.